贝那普利联合前列地尔治疗糖尿病肾病对尿白蛋白及细胞因子水平的影响

目的探究贝那普利联合前列地尔治疗糖尿病肾病对尿白蛋白和细胞因子水平的影响。方法选取我院2016年5月至2018年4月收治的150例糖尿病肾病患者作为研究对象,采用数字单双号随机分组法将其分为对照组和试验组,每组75例。对照组采用胰岛素结合贝那普利治疗,试验组在对照组的基础上增加前列地尔治疗。比较两组治疗前、后的24 h尿白蛋白、VEGF、TGF-β水平以及不良反应发生情况。结果治疗前,两组24 h尿白蛋白水平比较,差异无统计学意义(P>0.05);治疗后,两组24 h尿白蛋白水平均显著下降,且试验组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组VEGF、TGF-β水平比较,差异无统计学意义(P>0.05);治疗后,两组VEGF、TGF-β水平均显著降低,且试验组低于对照组,差异有统计学意义(P<0.05)。对照组不良反应总发生率为6.67%,试验组不良反应总发生率为8.00%,两组比较,差异无统计学意义(P>0.05)。结论贝那普利联合前列地尔应用于糖尿病肾病的治疗中,能够降低患者的尿白蛋白水平,促进尿白蛋白的排泄,抑制各细胞因子的表达,缓解患者的症状,并且不良反应少,安全性较高,值得推广。

Effects of benazepril combined with alprostadil on the levels of urinary albumin and cytokines in diabetic nephropathy

Objective To explore the effects of benazepril combined with alprostadil on the levels of urinary albumin and cytokine in diabetic nephropathy. Methods A total of 150 patients with diabetic nephropathy admitted in our hospital from May 2016 to April 2018 were selected as the study objects and divided into control group and experimental group accoding to digital single and double number random grouping method, with 75 cases in each group. The control group was treated with insulin combined with benazepril, and the experimental group was treated with alprostadil on the basis of the control group. The levels of 24 hours urinary albumin, VEGF, TGF before and after treatment and adverse reactions were compared between the two groups. Results Before treatment, there was no significant difference in 24 hours urinary albumin level between the two groups(P >0.05). After treatment, the 24 hours urinary albumin level in both groups decreased significantly, and that in the experimental group was lower than the control group, the differences were statistically significant(P<0.05). Before treatment, there were no significant differences in the levels of VEGF and TGF between the two groups(P>0.05). After treatment, the levels of VEGF and TGF in both groups decreased significantly, and those in the experimental group were lower than the control group, with statistically significant differences(P<0.05). The total incidence of adverse reactions was 6.67% in the control group and 8.00% in the experimental group, with no statistically significant difference between the two groups(P>0.05). Conclusion Benazepril combined with alprostadil in the treatment of diabetic nephropathy can reduce the level of urinary albumin in patients, promote the excretion of urinary albumin, inhibit the expression of various cytokines, and alleviate the symptoms of patients, with fewer adverse reactions and higher safety. It is worthy of promotion.